by Beth Cullen | May 11, 2022 | Investor Relations, Japan Focus
Control Bionics was featured in an article on JETRO’s site announcing the expansion of our AAC technology into Japan. The article discusses Control Bionics’ NeuroNode Trilogy system, which combines touch control and eye control in addition to EMG, to...
by Beth Cullen | May 10, 2022 | Education
At Control Bionics, we talk a lot about the power of 3, giving users more speed and less fatigue while using their speech generating device. But what exactly are those access methods and how do they work? This blog will walk through the different methods we offer with...
by Beth Cullen | May 3, 2022 | Investor Relations, Products
Control Bionics is excited to announce the integration of the Hiru eye gaze camera into our AAC solutions. With the addition of the Hiru to the NeuroNode Trilogy Systems, Control Bionics will be able to offer the latest in eye gaze technology. Hiru is the first...
by Beth Cullen | Apr 28, 2022 | Investor Relations
In the third quarter ended 31 March 2022, CBL sales through North American operations were recorded at AU$0.95 million. In the North American market alone, the company marked striking growth of 90% year-on-year in unit sales. The ASX-listed company has been able to...
by Beth Cullen | Apr 28, 2022 | Investor Relations, Products
At Control Bionics, we are constantly working towards our mission of making life-changing connections. Each day, we help bring our users closer to their communication goals. Now, the Cosmos Connect will help users connect in a different way. What is the Cosmos...
